Microscopic description:

The H&E stain shows multiple, irregularly shaped glands showing cribriform pattern and comedonecrosis and adjacent infiltrative crowded small glands with nuclear enlargement, hyperchromasia and prominent nucleoli.

P63/HMWCK/AMACR Triple stain was done offsite. P63 stain highlights the basal cells in continuous fashion and AMACR stain is negative in irregularly shaped glands with cribriform architecture confirming the diagnosis of intraductal carcinoma of prostate (vs HGPIN). The adjacent small crowded glands are p63 and MWCK negative and AMACR positive confirming the diagnosis of prostate adenocarcinoma.

Discussion:

Intraductal carcinoma of the prostate (IDC-P) is defined as a proliferation of prostate adenocarcinoma cells distending and spanning the lumen of pre-existing benign prostatic ducts and acini, with at least focal preservation of basal cells. Studies demonstrate that IDC-P is strongly associated with high-grade (Gleason grades 4/5), large-volume invasive prostate cancers.

Some of the architectural patterns in IDC-P exhibit architectural overlap with one of the main differential diagnoses, high-grade prostatic intraepithelial neoplasia (HGPIN). In these instances, additional diagnostic criteria for IDC-P, including marked nuclear pleomorphism, non-focal comedonecrosis (>1 duct showing comedonecrosis), markedly distended normal ducts/acini, positive nuclear staining for ERG, and cytoplasmic loss of PTEN by immunohistochemistry, can help make the distinction. This distinction between IDC-P and HGPIN is of critical importance because IDC-P has an almost constant association with invasive carcinoma and has negative clinical implications, including shorter relapse-free survival, early biochemical relapse, and metastatic failure rate after radiotherapy. Therefore, IDC-P should be reported in prostate biopsies and radical prostatectomies, regardless of the presence of an invasive component.

Table of IDC-P overlap
References:

Intraductal Carcinoma of the Prostate Gland: Recent Advances. Divatia MK, Ro JY. Yonsei Med J. 2016 Sep;57(5):1054-62. doi: 10.3349/ymj.2016.57.5.1054. PMID: 27401634; PMCID: PMC4960369.

Intraductal carcinoma of the prostate. Robinson B, Magi-Galluzzi C, Zhou M. Arch Pathol Lab Med. 2012 Apr;136(4):418-25. doi: 10.5858/arpa.2011-0519-RA. PMID: 22458904.

Intraductal carcinoma of the prostate: a critical re-appraisal. ) Varma M, Delahunt B, Egevad L, Samaratunga H, Kristiansen G. Virchows Arch. 2019 May;474(5):525-534. doi: 10.1007/s00428-019-02544-6. Epub 2019 Mar 1. PMID: 30825003; PMCID: PMC6505500.

Intraductal Carcinoma of Prostate (IDC-P), Grade Group, and Molecular Pathology: Recent Advances and Practical Implication Ashwyna Sunassee1*, Ghadah Al Sannaa1*, Jae Y. Ro1